American Gene Technologies (AGT) may be a little bit dizzy with all this spinning. The biotech has inked a blank-check deal for subsidiary Addimmune, signing off the HIV-focused unit to special purpose acquisition company 10X Capital Venture Acquisition Corp. III.

美国基因技术公司（AGT）可能会因为所有这些旋转而有点头晕。该生物技术公司为子公司Addimmune签署了空白支票协议，将艾滋病重点部门签署给特种收购公司10X资本风险收购公司III。

Addimmune spun out from AGT in June, taking a mid-stage HIV cell therapy with it. Now, AGT has entered a deal with 10X III to take the spinoff public, with all non-HIV assets being spun out into a separate entity that will keep AGT’s name. The deal, which is expected to close in the first quarter of 2024, has already been approved by both companies’ board of directors..

Addimmune于6月从AGT中分离出来，采用中期HIV细胞疗法。现在，AGT已经与10X III达成协议，将分拆公众，所有非HIV资产都被分离成一个单独的实体，将保留AGT的名字。该协议预计将于2024年第一季度结束，已获得两家公司董事会的批准。。

In relation to the proposal, 10X III and AGT have inked a non-binding letter of intent for a $50 million committed equity facility. Once the deal is final, Addimmune stockholders will move 100% of equity into the combined company.

关于该提案，10X III和AGT已经为5000万美元承诺的股权设施签署了一份无约束力的意向书。一旦交易结束，其他股东将100%的股权转移到合并公司。

The proposal represents a pre-money enterprise value of $500 million for Addimmune and also offers the potential for $300 million tied to various milestones.

该提案代表了Addimmune 5亿美元的资金前企业价值，并且还提供了与各种里程碑相关的3亿美元的潜力。

Addimmune will trade under ticker symbol “HIV,” with AGT CEO Jeff Galvin set to helm the new company.

Addimmune将在勾选符号“HIV”下交易，AGT首席执行官Jeff Galvin将领导新公司。

The biotech’s investigational HIV candidate, dubbed AGT103-T, is a single-dose autologous cell therapy designed to harden T cells against HIV infection and depletion. In 2021, Addimmune finished a phase 1 trial assessing the therapy in seven patients with HIV. The trial, alongside a separate sponsor-initiated follow-on study, showed active immune responses to HIV up to six months after dosing, according to AGT.

该生物技术公司的艾滋病研究候选人，被称为AGT103-T，是一种单剂量自体细胞疗法，旨在硬化T细胞抵抗艾滋病毒感染和消耗。2021年，Addimmune完成了一项评估7名HIV患者治疗的1期临床试验。根据AGT的说法，该试验与单独的赞助商发起的后续研究一起，在给药后6个月内显示出对HIV的主动免疫反应。

The clinical findings are the reason AGT formed the spin-off to focus on clinical development and eventual commercialization of a functional cure for HIV..

临床发现是AGT形成专注于HIV功能性治疗的临床开发和最终商业化的副产品的原因。。

“We believe that people living with HIV may no longer require lifelong treatment and we imagine a day when this disease no longer causes suffering or claims lives anywhere in the world,” CEO Galvin said in a Aug. 10 release.

首席执行官加尔文在8月10日的发布中说：“我们相信艾滋病毒感染者可能不再需要终身治疗，我们想象有一天这种疾病不再导致世界任何地方的痛苦或要求生活。